Faculty Collaboration Database

Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000 Dec;26(11):1179-84

Date

01/10/2001

Pubmed ID

11149728

DOI

10.1038/sj.bmt.1702685

Scopus ID

2-s2.0-0033665539 (requires institutional sign-in at Scopus site)   161 Citations

Abstract

Donor leukocyte infusion (DLI) has well-documented activity in CML, but the role of DLI in other diseases is less well defined. To evaluate the strategy in multiple myeloma (MM) we evaluated 25 MM patients from 15 centers who were treated with DLI. Patients with persistent or recurrent disease after allogeneic BMT received DLI from the original marrow donor (23 matched related, one mismatched family, and one matched unrelated). Chemotherapy was given before DLI in three patients. Two of 22 patients responded completely to DLI alone and three patients responded to the combination of DLI and chemotherapy. Nine patients who had not had sufficient disease control after DLI were given additional DLIs; five of these patients had either complete (two) or partial (three) responses. Thirteen of 25 evaluable patients developed acute GVHD and 11 of 21 evaluable patients developed chronic GVHD; all responders developed GVHD. No patients developed post-DLI pancytopenia. Four patients had responses which lasted >1 year after DLI, three patients had responses which lasted <1 year, and three patients had ongoing responses but with follow-up <1 year. In conclusion, DLI has anti-myeloma activity but the strategy is limited by no response or short duration of response in a significant percentage of patients and by significant GVHD in the majority of the responders.

Author List

Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W, Barrett AJ, Horowitz M, Collins RH

Authors

William R. Drobyski MD Professor in the Medicine department at Medical College of Wisconsin
Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow Transplantation
Combined Modality Therapy
Female
Graft vs Host Disease
Humans
Immunotherapy, Adoptive
Leukocyte Transfusion
Living Donors
Male
Middle Aged
Multiple Myeloma
Prospective Studies
Retrospective Studies